Recent Press Releases

VIVUS Reports Third Quarter 2015 Financial Results

MOUNTAIN VIEW, CA -- (Marketwired) -- 11/04/15 -- VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company commercializing and developing innovative, next-generation...

Pfizer Expands its Patient Assistance Program, Doubling the Income Eligibility Limit to Benefit Even More Patients Taking Pfizer Medicines

Thursday, November 5, 2015 - 8:00am EST In response to the ongoing challenges patients face in paying their out-of-pocket costs for their prescription medicines, Pfizer announced today that it will...

Endo Reports Third Quarter 2015 Financial Results

DUBLIN, Nov. 5, 2015 /PRNewswire/ -- Third quarter revenues of $746 million, a 14 percent increase from third quarter of 2014 Third quarter reported $3.84 diluted (GAAP) loss per share from...

ASTRAZENECA ANNOUNCES YEAR-TO-DATE AND Q3 2015 RESULTS

Financial highlights1 Total Revenue stable in the YTD at $18,309m. Resilient top-line performance underpinned continued investment in R&D. Core R&D costs up by 18% in Q3, reflecting the...

Collins, McCaskill Open Senate Investigation into Rx Drug Pricing, Announce Intention to Hold Hearings

FOR IMMEDIATE RELEASE NOVEMBER 4, 2015 Contact: Drew Pusateri: 202-228-6263 Collins, McCaskill Open Senate Investigation into Rx Drug Pricing, Announce Intention to Hold Hearings Senators request...

Mylan Receives U.S. FTC Clearance for Proposed Acquisition of Perrigo and Confirms Governance Changes for the Combined Mylan-Perrigo Company

HERTFORDSHIRE, England and PITTSBURGH, Nov. 3, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced the U.S. Federal Trade Commission ("FTC") has cleared the company's proposed...

Novartis nominating Elizabeth Doherty and Ton Buechner to the Board of Directors

Nominees for election by shareholders at Annual General Meeting (AGM) in February 2016 Basel, November 4, 2015 - The Novartis Board of Directors announced today, that it is nominating Ms. Elizabeth...

Zoetis to Acquire PHARMAQ, the Global Leader in Vaccines and Innovation for Health Products in Aquaculture

Purchase price of $765 million Strengthens core livestock business with industry-leading vaccines and pharmaceuticals for farmed fish, the fastest growing segment of animal health industry Gains...

Merck's Glucophage(R) Extended Release (XR) Can be Used for More Type 2 Diabetes Patients

 British regulatory authority approves Glucophage® Extended Release (XR) for type 2 diabetes patients with moderate renal impairment stage 3a or stable chronic heart failure  The approval is...

Shire to Acquire Dyax Corp, expanding and extending industry-leading Hereditary Angioedema (HAE) portfolio

Lead pipeline product, DX-2930, is a Phase 3-ready asset, offering potentially transformative prophylactic therapy for HAE DX-2930 has potential to expand HAE-treated patients and achieve annual...

Former Deputy Attorney General Appointed To Advise Valeant's Ad Hoc Committee

10/30/2015 LAVAL, Quebec, Oct. 30, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced today that the ad hoc committee appointed by Valeant's board...

Valeant To Terminate Relationship With Philidor

10/30/2015 LAVAL, Quebec, Oct. 30, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced today that it is severing all ties with Philidor Rx Services, LLC,...

Regeneron Announces EU Approval of EYLEA® (aflibercept) Injection for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization

Regeneron Announces EU Approval of EYLEA® (aflibercept) Injection for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization TARRYTOWN, N.Y., Oct. 30, 2015...

Mylan Third Quarter 2015 Constant Currency Adjusted Total Revenues Increase 36% and Adjusted Diluted EPS Increases 23% to $1.43

Mylan Expects to be at High End of Full Year 2015 Adjusted Diluted EPS Guidance Range of $4.15 to $4.35 Mylan Remains Steadfastly Committed To Our Value-Creating Offer for Perrigo HERTFORDSHIRE,...

ABBVIE REPORTS THIRD-QUARTER 2015 FINANCIAL RESULTS

- REPORTS THIRD-QUARTER ADJUSTED EPS OF $1.13, UP NEARLY 27 PERCENT AND EXCEEDING PREVIOUS GUIDANCE RANGE OF $1.04 TO $1.06; REPORTS GAAP EPS OF $0.74 - DELIVERS THIRD-QUARTER REVENUE OF $5.944...

Allergan plc Confirms Discussions Regarding Potential Business Combination Transaction With Pfizer Inc.

THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.4 OF IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 (THE "IRISH TAKEOVER RULES"). DUBLIN, Oct. 29, 2015 /PRNewswire/ -- Allergan plc...

Novo Nordisk increased operating profit by 51% in the first nine months of 2015 to DKK 38.3 billion

16% local currency operating profit growth adjusted for the NNIT divestment Sales increased by 23% in Danish kroner and by 9% in local currencies to DKK 79.1 billion. Sales of Victoza®...

SANOFI GREW SALES AND BUSINESS EPS(1) IN Q3 2015

Broad-based sales growth despite Diabetes sales erosion in the U.S. Group sales(2) increased 3.4% (up 9.2% on a reported basis) to €9,591 million Diabetes sales decreased 6.6%, as a...

Amgen's Third Quarter 2015 Revenues Increased 14 Percent To $5.7 Billion And Adjusted Earnings Per Share (EPS) Increased 18 Percent To $2.72

Amgen's Third Quarter 2015 Revenues Increased 14 Percent To $5.7 Billion And Adjusted Earnings Per Share (EPS) Increased 18 Percent To $2.72 Third Quarter 2015 GAAP EPS Increased 52 Percent to...